Dr. Liang Cheng joined the Institute of Human Immunology at Shenzhen Medical Academy of Research and Translation (SMART) as a  Principal Investigator in July 2026, where he established the DC Biology and Immunotherapy Laboratory. He received his Ph.D. in Cell Biology from the Institute of Biophysics, Chinese Academy of Sciences, and completed his postdoctoral training at the University of North Carolina at Chapel Hill (UNC-Chapel Hill). He previously served as Research Assistant Professor in the Department of Microbiology & Immunology at UNC-Chapel Hill and as Principal Investigator at the Medical Research Institute, Wuhan University (2020–2026), where he was awarded tenure in January 2026.

Dr. Cheng has long been dedicated to human dendritic cell (DC) immunology and immunotherapeutic strategies for chronic infectious diseases. His research has yielded a series of innovative contributions to peripheral immune tolerance and HIV cure strategies:

Discovered and defined a novel dendritic cell subset—homeostatic mature DC2 (DC2hm)—that regulates human peripheral tolerance (Immunity, 2026);

Elucidated the pDC-IFN-immunometabolic signaling axis as a core driver of HIV persistence and immune exhaustion (CMI, 2026; JCI series);

Developed a novel HIV cure strategy that integrates "activation-targeting-elimination" of the latent HIV reservoir.

His research has been supported by funding from the National Natural Science Foundation of China (NSFC) and the National Key Research and Development Program of China.

Major Awards and Honors

Third Prize, Chinese Medical Science and Technology Award (2022

Hubei Provincial Hundred Talents Program (Innovative Talent) (2021)

CROI-2018 New Investigator Scholarship (2018)

Research Directions

Dr. Liang Cheng's laboratory focuses on two interconnected frontiers in human immunology: dendritic cell (DC)-mediated immune tolerance and immunotherapy for chronic diseases — with a translational vision to convert fundamental immunological discoveries into clinically actionable precision strategies.

(1) DC-Mediated Immune Tolerance

We are dedicated to discovering new human DC subsets and deciphering their roles in immune balance and therapeutic targeting. Our discovery of DC2hm—a homeostatic mature DC subset that enforces peripheral tolerance through self‑antigen presentation and Treg induction—has reshaped the conceptual landscape of human immune tolerance. We are now dissecting DC2hm's functions across autoimmunity, inflammation, and cancer, while also pioneering cellular reprogramming to create next‑generation DC‑based therapies for autoimmune diseases, chronic infections, and malignancies.

(2) HIV/AIDS Functional Cure

We combine clinical samples, mechanistic studies, and humanized mouse models to uncover HIV immunopathogenesis and develop novel immunotherapies. Our earlier work defined the pDC–IFN–metabolic axis as a key driver of HIV persistence and T‑cell exhaustion. We are now engineering first‑in‑class biologics with a triple "reactivate–target–kill" function to clear latent reservoirs, alongside strategies to preserve virus‑specific T‑cell stemness—offering a dual‑pronged approach for long‑term immune control and a functional cure.

Selected Publications

1. M Lu^#, R Han^#, H Yang^#, L Yang^#, Q Zhao, J Wang, Z Yu, N Liu, Y Xu, F Luo, Y Mu, H Wang, F Luo, Z Wang, M Zhou, K Lin, H Chen, H Chen, W Zhou, X Chen, H Li, R Chen, Q Zhang*, L Wang*, L Cheng*. Homeostatic Maturation Programs Drive Human cDC2s into a Tolerogenic State. Immunity 2026 May 12;59(5):1201-1220.e13.

2. Y Xu, H Yang, L Yang, Q Zhang, L Cheng*. Febrile-Range Temperature Selectively Limits Sustained pDC-Derived IFN-α via Attenuation of STAT1-Dependent Feedback Signaling. Cell Insight 2026 (Available online 24 June 2026, 100344)

3. L Cheng*, G Li, F Luo, W Bi, M Lu, N Liu, Q Zhao, R Han, H Wang, H Yang, J Ma, W Hu, H Yu, W Hou, Y Xiong, N Goonetilleke, RB Jones, L Su*. Persistent IFN-I Signaling Inhibits Mitochondrial Oxidative Metabolism in CD8+ T Cells during HIV-1 Infection under cART. Cellular & Molecular Immunology 2026 May;23(5):534-545.

4. R Han, Haisheng Yu, G Li, L Su*, L Cheng*. Persistent Type I Interferon Signaling Impairs Innate Lymphoid Cells During HIV-1 Infection Under Suppressive ART. Viruses. 2025 Aug 8;17(8):1099

5. G Li, Y Lou, J Ma, L Cheng, H Yu, O Tsahouridis, X He, M Funaki, J Ahodantin, W Bi, J Chen, X Fan, S Sharaf, N Goonetilleke, R.B. Jones, S Kottilil, P Mathur, L Su*. Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8+ T cells during chronic HIV-1 infection. Sci Transl Med.2025 Nov 5;17(823):eadr3930.

6. L Cheng, Q Wang, G Li, J Ma, H Yu, F Yasui, Z Zhang, S Zurawski, G Zurawski, Y Levy*, L Su*. TLR3 agonist/CD40-targeting vaccination induces T cell response and reduces HIV-1 reservoirs. The Journal of Clinical Investigation. 2018 128(10):4387-4396.

7. L Cheng^#, J Ma^#, J Li^#, D Li, G Li, F Li, Q Zhang, H Yu, F Yasui, C Ye, L-C Tsao, Z Hu, L Su*, L Zhang*. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. The Journal of Clinical Investigation.2017 127(1), 269-279.  

Recruitment Information

We are currently recruiting assistant research fellows, outstanding postdoctoral fellows and research assistants who are aspiring to further their academic careers, both domestically and internationally. We warmly welcome talented individuals with a strong interest in DC immunology, HIV immunotherapy, tumor immunology, and related research fields to join us. Please visit: smart.org.cn/career/research-lab/1215.html